



PuriCore plc (“PuriCore” or “the Company”)

Interim Management Statement

Q1 2008 Sales Increase 89% over Prior Year: 128% in Food Safety and 68% in UK Endoscopy

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 29 April 2008 — PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today issues its first Interim Management Statement as required by the UK Listing Authority’s Disclosure and Transparency Rules, covering the period 1 January 2008 to the date of this announcement. PuriCore also announces its Preliminary Results for the year ended 31 December 2007 today in a separate release.

Financial Results

- Q1 2008 sales of approximately \$9.1 million, up 89% versus Q1 2007
 - Food Safety revenue \$4.3 million, 128% increase
 - UK Endoscopy revenue \$4.7 million, 68% increase

Operational Highlights

- \$11 million Sterilox Food Safety contract announced for another top-five supermarket retailer
- Sterilox Solution demonstrated to be highly effective against pandemic H5N1 avian influenza
- In advanced discussions with several lenders to raise additional capital
- Sterilox Solution approved for Organic Food production, processing, and handling

Outlook

With a strong current order book and further anticipated order flow in both core businesses, PuriCore foresees significant top-line organic growth in 2008. The higher sales levels, combined with improving margins throughout the year, will enable the Company to achieve additional leverage of operations and expansion into new markets.

Greg Bosch, Chief Executive of PuriCore, said:

“PuriCore is off to a strong start to 2008 in both our US Food Safety and UK Endoscopy businesses. First quarter revenue grew almost 90% versus Q1 2007, while operating expenses were held at levels similar to prior year. We anticipate continued significant growth throughout the year as we capitalise on increasing market share and entrance into new markets.”

Enquiries:

Ben Brewerton
Susan Quigley
Financial Dynamics
+44 (0) 20 7831 3113

Greg Bosch, CEO
Keith A. Goldan, CFO
PuriCore
+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, Avian Influenza, HIV, Polio Virus, Helicobacter pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All 2008 financials are unaudited.